Baird Capital has invested in independent health and life sciences consultancy and market access specialist Newmarket Strategy.
Financial details of the transaction have not been disclosed.
The growth capital investment from Baird Capital’s Global Private Equity Fund will be used to support Newmarket’s continued growth.
Founded in 2021, Newmarket works with clients across the health and life sciences sectors to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. Its clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers.
The deal follows a number of investments by Baird in the pharma services sector, including Campbell Alliance, Prescient and Blue Matter.
Michael Holgate, partner with Baird Capital’s Global Private Equity team said: ‘We are excited to support Newmarket’s ambition to be the leader in its field. The team brings a high level of expertise, and the services they provide address a critical need across the clients they serve.’
Newmarket Strategy CEO Ed Jones added: ‘We were hugely impressed by Baird Capital’s team and partnership style, by their proven expertise and by the commitment they show to our sector. We are immensely proud of the hard work by all our team to date, and of the continued faith shown by our valued clients.’
Baird Capital was advised by Squire Patton Boggs (legal), Clearwater (corporate finance), T4 (voice of customer), Candesic (commercial diligence), BDO (financial & tax), New Street Consulting (management), and WTW (insurance). Newmarket was advised by JMW (legal) and MHA (corporate advisory).
©2025 All rights reserved LaingBuisson 
